Echocardiographic assessment of hypertensive patients with or without hyperhomocysteinemia

Clinical and Experimental Hypertension

Volumn 36, Issue 3, 2014, Pages 181-186

  Zheng, Huan ^a   Li, Ye ^b   Xie, Nanzi ^a   Xu, Huifeng ^a   Huang, Junling ^a   Luo, Ming ^a  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^b Key Laboratory of Arrhythmias of Ministry of Education   (China)

Author keywords

Hyperhomocysteinemia; Hypertension; Left ventricular function; Tei index

Indexed keywords

HOMOCYSTEINE;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOLOGIST; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; ECHOCARDIOGRAPH; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ULTRASOUND; AGED; BLOOD; COMPLICATION; DIASTOLE; HEART VENTRICLE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ADULT; AGED; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MALE; MIDDLE AGED; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84898417153     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2013.804542     Document Type: Article

References (34)

1. Gardin JM, Drayer JI, Weber M, et al. Doppler echocardiographic assessment of left ventricular systolic and diastolic function in mild hypertension. Hypertension 1987;9:90-6.
2. Tarazi RC. The heart in hypertension. N Engl J Med 1985;312: 308-9.
3. Lim U, Cassano PA. Homocysteine and blood pressure in the 3rd National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002;156:1105-13.
4. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
5. Shankar A, Wang JJ, Chua B, et al. Positive association between plasma homocysteine level and chronic kidney disease. Kidney Blood Press Res 2008;31:55-62.
6. Ambrosch A, Dierkes J, Lobmann R, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabet Med 2001;18:185-92.
7. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288:2015-22.
8. Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 1995;26:135-6.
9. Takasaki K, Miyata M, Imamura M, et al. Left ventricular dysfunction assessed by cardiac time interval analysis among different geometric patterns in untreated hypertension. Circ J 2012; 76:1409-14.
10. Schwammenthal E, Adler Y, Amichai K, et al. Prognostic value of global myocardial performance indices in acute myocardial infarction. Chest 2003;124:1645-51.
11. Bruch C, Schmermund A, Marin D, et al. Tei-Index in patients with mild-to-moderate congestive heart failure. Eur Heart J 2000;21: 1888-95.
12. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 1992;117:502-10.
13. Perrone-Filardi P, Bacharach SL, Dilsizian V, et al. Effects of regional systolic asynchrony on left ventricular global diastolic function in patients with coronary artery disease. J Am Coll Cardiol 1992;19:739-44.
14. Yamamoto K, Nishimura RA, Chaliki HP, et al. Determination of left ventricular filling pressure by Doppler echocardiography in patients with coronary artery disease: critical role of left ventricular systolic function. J Am Coll Cardiol 1997;30: 1819-26.
15. Boudoulas H. Diastolic time: the forgotten dynamic factor. Implications for myocardial perfusion. Acta Cardiol 1991;46:61-71.
16. Brazier J, Cooper N, Buckberg G. The adequacy of subendocardial oxygen delivery: the interaction of determinants of flow, arterial oxygen content and myocardial oxygen need. Circulation 1974;49: 968-77.
17. Ascione L, De Michele M, Accadia M, et al. Myocardial global performance index as a predictor of in-hospital cardiac events in patients with first myocardial infarction. J Am Soc Echocardiogr 2003;16:1019-23.
18. Pellett AA, Tolar WG, Merwin DG, et al. The Tei index: methodology and disease state values. Echocardiography 2004;21: 669-72.
19. Tei C, Nishimura RA, Seward JB, et al. Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterizeation measurements. J Am Soc Echocardiogr 1997;9:169-78.
20. Badiou S, Dupuy AM, Jaussent I, et al. Homocysteine as a determinant of left ventricular ejection fraction in patients with diabetes. Clin Chem Lab Med 2012;50:1099-106.
21. Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. Cardiol J 2003;289:1251-7.
22. Agoston-Coldea L, Mocan T, Gatfosse M, et al. Plasma homocyst-eine and the severity of heart failure in patients with previous myocardial infarction. Cardiol J 2011;18:55-62.
23. Joseph J, Shekhawat NS, Devi S, et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol 2003;285:H679-86.
24. Wocial B, Berent H, Kostrubiec M, et al. Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension. Blood Press 2002;11:201-5.
25. Cesari M, Zanchetta M, Burlina A, et al. Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. Arterioscler Thromb Vasc Biol 2005;25: 115-21.
26. Lentz SR. Homocysteine and vascular dysfunction. Life Sci 1997; 61:1205-15.
27. Zhou J, Austin RC. Contributions of hyperhomocysteinemia to atherosclerosis: causal relationship and potential mechanisms. Biofactors 2009;35:120-9.
28. Zivkovic V, Jakovljevic V, Djordjevic D, et al. The effects of homocysteine-related compounds on cardiac contractility, coronary flow, and oxidative stress markers in isolated rat heart. Mol Cell Biochem 2012;370:59-67.
29. Alter P, Rupp H, Rominger MB, et al. Association of hyperhomo-cysteinemia with left ventricular dilatation and mass in human heart. Clin Chem Lab Med 2010;48:555-60.
30. Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005;5:124-39.
31. Guéant Rodriguez RM, Spada R, Pooya S, et al. Homocysteine predicts increased NT-pro-BNP through impaired fatty acid oxidation. Int J Cardiol 2012. [Epub ahead of print]. doi:10.1016/j.ijcard.2012.03.047.
32. Sundstrom J, Vasan RS. Homocysteine and heart failure: a review of investigations from the Framingham Heart Study. Clin Chem Lab Med 2005;43:987-92.
33. Reddy HK, Tjahja IE, Campbell SE, et al. Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation. Mol Cell Biochem 2004;264:183-91.
34. Au-Yeung KK, Woo CW, Sung FL, et al. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004;94:28-36.